ALXO Stock Price, Chart, Stats & News
ALX Oncology Holdings Inc. (ALXO) does not currently pay a dividend.
ALXO chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -172.23% |
ROE | -182.01% |
D/E | 0.20x |
Interest coverage ratio | -64.93x |
ALXO valuation
P/E | – |
P/S | – |
P/B | 4.26x |
P/CF | -1.32x |
P/FCF | -1.31x |
P/OCF | -1.32x |
PEG | -0.17x |
EV multiple | -1.22x |
About
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma.
Similar securities
Based on sector and market capitalization
